ACRO BIOMEDICAL CO., LTD. Amortization of Deferred Sales Commissions
ACRO BIOMEDICAL CO., LTD. (ACBM) reported Amortization of Deferred Sales Commissions of $3.12 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfDeferredSalesCommissions · last filed 2023-08-14
- ACRO BIOMEDICAL CO., LTD. amortization of deferred sales commissions for the quarter ending 2023-06-30 was $3.12M, a 20.48% decline year-over-year.
- ACRO BIOMEDICAL CO., LTD. amortization of deferred sales commissions for the quarter ending 2023-03-31 was $3.93M, a 0.00% change year-over-year.
- ACRO BIOMEDICAL CO., LTD. amortization of deferred sales commissions for the quarter ending 2022-09-30 was $3.93M.
- ACRO BIOMEDICAL CO., LTD. amortization of deferred sales commissions for the quarter ending 2022-06-30 was $3.93M.
- ACRO BIOMEDICAL CO., LTD. amortization of deferred sales commissions for fiscal 2022 was $15.71M, a 105.35% increase from fiscal 2021.
- ACRO BIOMEDICAL CO., LTD. amortization of deferred sales commissions for fiscal 2021 was $7.65M.
| Period end | Amortization of Deferred Sales Commissions 3 month | Amortization of Deferred Sales Commissions 6 month | Amortization of Deferred Sales Commissions 9 month | Amortization of Deferred Sales Commissions 12 month |
|---|---|---|---|---|
| 2023-06-30 | $3.12M 10-Q · filed 2023-08-14 | $7.05M 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | $3.93M 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $15.71M 10-K · filed 2023-07-21 | |||
| 2022-09-30 | $3.93M 10-Q · filed 2022-11-21 | $7.86M derived: sum of 2 quarters · filed 2023-08-14 | $11.78M derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-06-30 | $3.93M 10-Q · filed 2023-08-14 | $7.86M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $3.93M 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $7.65M 10-K · filed 2023-07-21 | |||
| 2021-06-30 | $804.65K 10-Q · filed 2022-08-12 |